Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 5, pp 1070–1083 | Cite as

Prevalence and predictors of digoxin utilization among heart failure patients with reduced ejection fraction in Qatar

  • Alaa Abdullah Rahhal
  • Ahmed AwaisuEmail author
  • Kawthar M. Tawengi
  • Safae AbuYousef
  • Lylia Mekideche
Research Article
  • 136 Downloads

Abstract

Background Digoxin is a cardiac glycoside that is recommended by clinical practice guidelines to be used in patients with heart failure with reduced ejection fraction (HFrEF) who still have persistent symptoms despite optimal medical therapy. However, this recommendation is based on limited and old trial data. Moreover, pharmacoepidemiologic studies are important in determining the prevalence of digoxin use and factors influencing this. Objective This study aimed to determine the prevalence and the predictors of digoxin utilization among patients with HFrEF with or without atrial fibrillation (AF) in Qatar. Setting Heart Hospital, a specialized tertiary care center in Qatar. Methods A retrospective observational study was conducted using Cerner electronic medical records. Subjects included 736 patients admitted between January 1, 2013 and December 31, 2014 with the diagnosis of HFrEF with or without AF. Two groups of patients were studied: digoxin users and digoxin non-users at index hospitalization until discharge. Univariate and multivariate binary logistic regression analyses were conducted to determine the predictors of digoxin prescription. Data analyses were performed using IBM SPSS® version 23.0. Main outcome measures Prevalence and predictors of digoxin prescriptions among HFrEF patients measured in percentages and odds rations, respectively. Results A total of 736 patients who met the inclusion criteria were analyzed for digoxin prevalence, including 80 patients (11%) who were newly prescribed digoxin during the index hospitalization. After adjusting for patient demographics and clinical characteristics, the use of thiazide diuretics (aOR = 10.14, CI 2.31–44.6, p value = 0.002), concurrent AF (aOR = 8.2, CI 3.11–21.7, p < 0.001), and an ejection fraction (EF) <25% (aOR = 3.2, CI 1.5–6.8, p value = 0.002) significantly predicted digoxin prescriptions among patients with HFrEF. Conclusion The rate of digoxin prescription among patients with HFrEF in Qatar is relatively low. The strongest predictors of digoxin use in HFrEF patients were the concomitant use of thiazide diuretics and concurrent diagnosis of AF. The findings may potentially serve as useful guides for the rational utilization of digoxin in patients with HFrEF.

Keywords

Atrial fibrillation Digoxin Heart failure Prescription Predictors Qatar Retrospective study 

Notes

Acknowledgements

The authors would like to thank the staff at the Medical Record Unit of the HH in Qatar who provided access to the required data.

Funding

This study was supported by the Hamad Medical Corporation (Grant No. 16228/16).

Conflicts of interest

The authors declare no conflict of interest in this study. The funders had no role in the design, planning and implementation of the project. The content is the sole responsibility of the authors.

References

  1. 1.
    Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–209.CrossRefPubMedGoogle Scholar
  2. 2.
    Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(5):525–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):1810–52.CrossRefPubMedGoogle Scholar
  4. 4.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRefPubMedGoogle Scholar
  5. 5.
    The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.CrossRefGoogle Scholar
  6. 6.
    Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail. 2010;16(5):191–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Arnold SB, Byrd RC, Meister W, Melmon K, Cheitlin MD, Bristow JD, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med. 1980;303:1443–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Aljundi AH, Mohammed SF, Patel A, Singh R, Arabi A, AlBinali HA, et al. Inotropic agents use in patients hospitalized with acute decompensated heart failure: a retrospective analysis from a 22-year registry in a Middle-Eastern Country (1991-2013). BMC Cardiovasc Disord. 2016;16(1):47.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Al-Zakwani I, Panduranga P, Zubaid M, Sulaiman K, Rashed WA, Alsheikh-Ali AA, et al. Impact of digoxin on mortality in patients with atrial fibrillation stratified by heart failure: findings From Gulf Survey of Atrial Fibrillation Events in the Middle East. J Cardiovasc Pharmacol Ther. 2016;21(3):273–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Konstantinou DM, Karvounis H, Giannakoulas G. Digoxin in heart failure with a reduced ejection fraction: a risk factor or a risk marker? Cardiology. 2016;134(3):311–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Virgadamo S, Charnigo R, Darrat Y, Morales G, Elayi CS. Digoxin: a systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World J Cardiol. 2015;7(11):808–16.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36(28):1831–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin converting enzyme inhibitors. Circulation. 1995;92:1801–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Slatton ML, Irani WN, Hall SA, Marcoux LG, Page RL, Grayburn PA, et al. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? J Am Coll Cardiol. 1997;29:1206–13.CrossRefPubMedGoogle Scholar
  15. 15.
    Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312–8.Google Scholar
  16. 16.
    Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Alaa Abdullah Rahhal
    • 1
  • Ahmed Awaisu
    • 1
    Email author
  • Kawthar M. Tawengi
    • 1
  • Safae AbuYousef
    • 1
  • Lylia Mekideche
    • 1
  1. 1.Qatar UniversityDohaQatar

Personalised recommendations